Evidence map›Paper›PMID 31209787›Full record

ArticleNeurotoxicity research2019

Diffusion Kurtosis Imaging Detects Microstructural Changes in a Methamphetamine-Induced Mouse Model of Parkinson's Disease.

Anas Arab, Jana Ruda-Kucerova, Alzbeta Minsterova, Eva Drazanova, Nikoletta Szabó, Zenon Starcuk, Irena Rektorova, Amit Khairnar

Abstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. White matter changes in Parkinson's disease.NPJ Parkinson's disease · 2023
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. An Introduction to Kurtosis Fractional Anisotropy.AJNR. American journal of neuroradiology · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Anas ArabDepartment of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
Jana Ruda-KucerovaDepartment of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. jkucer@med.muni.cz.ORCID http://orcid.org/0000-0002-1846-0799
Alzbeta MinsterovaApplied Neuroscience Research Group, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Eva DrazanovaDepartment of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
Nikoletta SzabóDepartment of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, Szeged, Hungary.
Zenon StarcukInstitute of Scientific Instruments of the Czech Academy of Sciences, Brno, Czech Republic.
Irena RektorovaApplied Neuroscience Research Group, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Amit KhairnarApplied Neuroscience Research Group, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Central European Institute of Technology · CZMasaryk University · CZCzech Academy of Sciences, Institute of Scientific Instruments · CZ

Funding

EFOP EFOP-3.6.1-16-2016-00008European Regional Development Fund No. CZ.02.1.01/0.0/0.0/16_013/0001775Masarykova Univerzita Junior Scientist Support ProjectMinisterstvo Školství, Mládeže a Tělovýchovy CZ.1.05/2.1.00/01.0017Ministerstvo Školství, Mládeže a Tělovýchovy LM2015062Ministerstvo Školství, Mládeže a Tělovýchovy MUNI/A/1550/2018Ministerstvo Školství, Mládeže a Tělovýchovy (CZ) RVO:68081731Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal (HU) 2017-1.2.1-NKP-2017-00002Országos Tudományos Kutatási Alapprogramok KTIA_13_NAP-A-II/20
6 · The paper itself

Abstract

Methamphetamine (METH) abuse is known to increase the risk of Parkinson's disease (PD) due to its dopaminergic neurotoxicity. This is the rationale for the METH model of PD developed by toxic METH dosing (10 mg/kg four times every 2 h) which features robust neurodegeneration and typical motor impairment in mice. In this study, we used diffusion kurtosis imaging to reveal microstructural brain changes caused by METH-induced neurodegeneration. The METH-treated mice and saline-treated controls underwent diffusion kurtosis imaging scanning using the Bruker Avance 9.4 Tesla MRI system at two time-points: 5 days and 1 month to capture both early and late changes induced by METH. At 5 days, we found a decrease in kurtosis in substantia nigra, striatum and sensorimotor cortex, which is likely to indicate loss of DAergic neurons. At 1 month, we found an increase of kurtosis in striatum and sensorimotor cortex and hippocampus, which may reflect certain recovery processes. Furthermore, we performed tract-based spatial statistics analysis in the white matter and at 1 month, we observed increased kurtosis in ventral nucleus of the lateral lemniscus and some of the lateral thalamic nuclei. No changes were present at the early stage. This study confirms the ability of diffusion kurtosis imaging to detect microstructural pathological processes in both grey and white matter in the METH model of PD. The exact mechanisms underlying the kurtosis changes remain to be elucidated but kurtosis seems to be a valuable biomarker for tracking microstructural brain changes in PD and potentially other neurodegenerative disorders.

Indexed as

AnimalsBehavior, AnimalBrainDiffusion Magnetic Resonance ImagingDisease Models, AnimalDopamine AgentsMaleMethamphetamineMice, Inbred C57BLParkinson Disease, SecondaryDopamine AgentsMethamphetamineBehaviourDiffusion kurtosis imagingMethamphetamineMiceMRIParkinson’s diseaseTract-based spatial statistics

Identifiers

PMID31209787
OpenAlexW2950764839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.